Vadivarhe Speci.

Why is Vadivarhe Speciality Chemicals Ltd falling/rising?

As of 23-Jun, Vadivarhe Speciality Chemicals Ltd's stock price is stable at 28.35, with a recent 5.00% increase over the past week and a significant 42.11% rise over the past month. However, the company faces long-term financial challenges, including a high Debt to EBITDA ratio and negative EBITDA, which may impact its future performance.

As of 23-Jun, Vadivarhe Speciality Chemicals Ltd's stock price is currently stable at 28.35, showing no change (0.00%). Despite this stability in the current price, the stock has demonstrated a notable upward trend over the past week, with a rise of 5.00%, significantly outperforming the Sensex, which has decreased by 0.69% during the same period. Over the past month, the stock has surged by 42.11%, while the Sensex has only increased by 0.44%. Year-to-date, the stock has gained an impressive 60.62%, contrasting sharply with the Sensex's decline of 8.82%.<BR><BR>Today's performance indicates that Vadivarhe Speciality Chemicals Ltd has outperformed its sector by 0.99%. The stock is also trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which suggests a positive momentum. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 42.86% against the 5-day average.<BR><BR>However, it is important to consider the underlying challenges facing the company. The long-term fundamental strength is weak, as the company has not declared results in the last six months, and it has a high Debt to EBITDA ratio of -6.54 times, indicating low ability to service debt. Furthermore, the company has recorded a negative EBITDA of Rs. -4.86 crore and a significant profit decline of -299% over the past year, which raises concerns about its financial health.<BR><BR>In summary, while Vadivarhe Speciality Chemicals Ltd has shown strong short-term performance and positive trading indicators, the underlying financial weaknesses and risks may contribute to a cautious outlook for the stock in the long term.

Which are the latest news on Vadivarhe Speci.?

What does Vadivarhe Speci. do?

Vadivarhe Speciality Chemicals Ltd is a Micro Cap company in the Chemicals & Petrochemicals industry, incorporated in 2009, with recent net sales of 6 Cr and a net profit of -3 Cr as of December 2021. The company has a market cap of INR 34 Cr and notable financial metrics include a debt-equity ratio of -7.03 and a return on equity of 176.02%.

Overview: <BR>Vadivarhe Speciality Chemicals Ltd operates in the Chemicals & Petrochemicals industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>The company was incorporated on February 23, 2009. Prior to its incorporation, it was promoted by Mr. Sunil Haripant Pophale under the name Fem Care Pharma Ltd, which was later taken over by Dabur India Limited in 2009. The latest quarterly results reported net sales and profit for December 2021.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 6 Cr (Quarterly Results - Dec 2021) <BR>Most recent Net Profit: -3 Cr (Quarterly Results - Dec 2021) <BR>Market-cap value: INR 34 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 42 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -7.03 <BR>Return on Equity: 176.02% <BR>Price to Book: -7.66<BR><BR>Contact Details: <BR>Address: Gat No 204 Vadivarhe Igatpu, Igatpuri Maharashtra: 422403 <BR>Tel: 91-2553-282200 <BR>Email: cs@vscl.co.in / inquiry@vscl.in <BR>Website: http://www.vscl.net.in

How big is Vadivarhe Speci.?

As of 10th June, Vadivarhe Speciality Chemicals Ltd has a market capitalization of 34.00 Cr, with recent net sales of 23.77 Cr and a net profit loss of 7.52 Cr. Shareholder's funds are at a loss of 2.78 Cr, and total assets are valued at 42.73 Cr.

As of 10th June, Vadivarhe Speciality Chemicals Ltd has a market capitalization of 34.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest 4 quarters, the company reported Net Sales of 23.77 Cr. However, it experienced a loss of 7.52 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds stand at a loss of 2.78 Cr and Total Assets are valued at 42.73 Cr.

Who are in the management team of Vadivarhe Speci.?

The management team of Vadivarhe Speci. consists of Sunil H Pophale (Director), Meena S Pophale (Whole-time Director), Prasanna P Rege, Ravindra K Paranjpe, and Uttara A Kher (all Independent Directors), and Pramod W Gajare (Whole-time Director).

The management team of Vadivarhe Speci. includes the following members:<BR><BR>1. **Sunil H Pophale** - Director<BR>2. **Meena S Pophale** - Whole-time Director<BR>3. **Ravindra K Paranjpe** - Independent Director<BR>4. **Prasanna P Rege** - Independent Director<BR>5. **Uttara A Kher** - Independent Director<BR>6. **Pramod W Gajare** - Whole-time Director<BR><BR>If you need more details about their roles or contributions, feel free to ask!

Who are the peers of the Vadivarhe Speci.?

Vadivarhe Speci.'s peers include Arvee Laborat., Indian Phosphate, Vital Chemtech, and others. Management risks vary, with excellent growth at Indian Emuls, while Vadivarhe Speci. has a 1-year return of 0.00%, better than Indian Emuls but worse than Sanginita Chemi.

Peers: The peers of Vadivarhe Speci. are Arvee Laborat., Indian Phosphate, Vital Chemtech, Jocil, Hindcon Chemical, Par Drugs & Che., Paragon Fine, Indian Emuls, Sanginita Chemi., and Unilex Colour &C.<BR><BR>Quality Snapshot: Excellent management risk is observed at Paragon Fine and Indian Phosphate, while Average management risk is found at Hindcon Chemical, Jocil, Par Drugs & Che., Indian Emuls, and the rest. Below Average management risk is noted at Arvee Laborat., Vital Chemtech, Sanginita Chemi., Unilex Colour &C. Growth is Excellent at Indian Emuls, while Below Average growth is seen at Arvee Laborat., Vital Chemtech, Indian Phosphate, Jocil, Hindcon Chemical, Par Drugs & Che., Paragon Fine, and the rest. Below Average capital structure is noted at Vadivarhe Speci., Arvee Laborat., Vital Chemtech, Sanginita Chemi., and Unilex Colour &C, while Good capital structure is observed at Hindcon Chemical and the rest, with Excellent capital structure at Indian Phosphate, Jocil, Par Drugs & Che., and Paragon Fine.<BR><BR>Return Snapshot: Sanginita Chemi. has the highest 1-year return at 217.14%, while Indian Emuls has the lowest at -73.32%, with Vadivarhe Speci.'s 1-year return at 0.00% being better than Indian Emuls but worse than Sanginita Chemi. Additionally, several peers, including Hindcon Chemical, Par Drugs & Che., Indian Emuls, and Unilex Colour &C, have negative six-month returns.

Should I buy, sell or hold Vadivarhe Speciality Chemicals Ltd?

How has been the historical performance of Vadivarhe Speci.?

Vadivarhe Speci. has experienced declining financial performance, with net sales dropping from 43.68 Cr in March 2023 to 37.91 Cr in March 2025, and significant losses in operating profit and profit after tax. The company's total liabilities increased, indicating financial pressure and ongoing challenges in cash flow generation.

Answer:<BR>The historical performance of Vadivarhe Speci. shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Vadivarhe Speci. reported net sales of 37.91 Cr in March 2025, a decline from 40.08 Cr in March 2024 and 43.68 Cr in March 2023, which were significantly higher than the 21.45 Cr recorded in March 2022. The total operating income followed a similar trend, decreasing from 40.08 Cr in March 2024 to 37.91 Cr in March 2025. The company's total expenditure increased to 44.32 Cr in March 2025, up from 36.03 Cr in March 2024, leading to an operating profit (PBDIT) of -6.14 Cr in March 2025, down from 4.54 Cr in the previous year. Profit before tax also fell to -9.27 Cr in March 2025, compared to 1.51 Cr in March 2024. Consequently, the profit after tax was -9.27 Cr in March 2025, a significant drop from 0.06 Cr in March 2024. The company's total liabilities increased to 42.73 Cr in March 2025, while total assets were reported at 42.73 Cr, indicating a balance sheet under pressure. Cash flow from operating activities was -7.00 Cr in March 2025, reflecting ongoing challenges in generating positive cash flow. Overall, the financial performance of Vadivarhe Speci. has shown a downward trajectory in recent years, particularly in profitability and cash flow metrics.

Who are the top shareholders of the Vadivarhe Speci.?

The top shareholder of Vadivarhe Speci. is Meena Sunil Pophale, holding 47.24%, with no pledged promoter holdings. The highest public shareholder is Sanjaykumar Harikishan at 1.67%, while individual investors own 26.7% of the shares.

The top shareholders of Vadivarhe Speci. are primarily the promoters, with Meena Sunil Pophale holding the largest share at 47.24%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Sanjaykumar Harikishan, who owns 1.67%. Additionally, individual investors collectively hold 26.7% of the company's shares.

Is Vadivarhe Speci. overvalued or undervalued?

As of April 25, 2023, Vadivarhe Speciality is classified as risky and overvalued, with poor financial metrics including a PE ratio of -4.44 and a year-to-date return of -39.39%, significantly underperforming compared to its peers and the Sensex.

As of 25 April 2023, the valuation grade for Vadivarhe Speciality has moved from does not qualify to risky, indicating a significant shift in its financial standing. The company appears to be overvalued based on its current metrics, which include a PE ratio of -4.44, an EV to EBITDA of -12.38, and a ROE of -119.89%. These ratios suggest that the company is struggling to generate positive returns and is facing considerable financial challenges.<BR><BR>In comparison to its peers, Vadivarhe Speciality's valuation stands out negatively. For instance, Solar Industries India Ltd. is classified as very expensive with a PE ratio of 123.77, while Godrej Industries Ltd. is considered attractive with a PE ratio of 46.63. The stark contrast in valuations highlights the difficulties faced by Vadivarhe Speciality. Additionally, the company's year-to-date return of -39.39% significantly underperforms the Sensex's gain of 6.20%, further reinforcing the notion that it is currently overvalued in the market.

What is the technical trend for Vadivarhe Speci.?

As of May 29, 2025, Vadivarhe Speci. shows a bearish trend with moderate strength, supported by bearish daily moving averages and KST, despite conflicting signals from the MACD.

As of 29 May 2025, the technical trend for Vadivarhe Speci. has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. The weekly MACD is mildly bullish, but the monthly MACD indicates a bearish trend, which is a conflicting signal. The daily moving averages are bearish, reinforcing the negative outlook. Additionally, both the weekly and monthly KST are bearish, and Bollinger Bands are mildly bearish across both time frames. There are no significant signals from the RSI or Dow Theory, which show no trend. Overall, the bearish indicators dominate, suggesting caution for investors.

When is the next results date for Vadivarhe Speci.?

No Upcoming Board Meetings

Has Vadivarhe Speci. declared dividend?

No Dividend History Available